Claims for Patent: 7,192,938

Summary for Patent: 7,192,938

Title:	Method of treatment using bisphosphonic acid
Abstract:	The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month.
Inventor(s):	Bauss; Frieder (Neuhofen, DE), Pichler; Bernhard (Ketsch, DE), Turley; Stephen (Bottmingen, CH)
Assignee:	Hoffmann-La Roche Inc. (Nutley, NJ)
Application Number:	10/998,849
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,192,938
Patent Claims:	1. A method for treating or inhibiting osteoporosis comprising commencing treatment by orally administering to a subject in need of such treatment, a first dose, on a single day, of a pharmaceutical composition comprising from about 100 mg to about 150 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to about 100 mg to about 150 mg of said bisphosphonic acid and continuing said treatment by orally administering, once monthly on a single day, a pharmaceutical composition comprising from about 100 mg to about 150 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is eguivalent to from about 100 mg to about 150 mg of bisphosphonic acid. 2. The method according to claim 1, wherein the pharmaceutical composition comprises about 100 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to about 100 mg of bisphosphonic acid. 3. The method according to claim 1, wherein the pharmaceutical composition comprises about 150 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to about 150 mg of bisphosphonic acid. 4. The method of claim 1, wherein the pharmaceutical composition comprises 100 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to 100 mg of bisphosphonic acid. 5. The method of claim 1 wherein the pharmaceutical composition comprises 150 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to 150 mg of bisphosphonic acid. 6. The method of claim 1 wherein said bisphosphonic acid is risedronic acid or a pharmaceutically acceptable salt thereof. 7. The method of claim 2 wherein said bisphosphonic acid is risedronic acid or a pharmaceutically acceptable salt thereof. 8. The method of claim 3 wherein said bisphosphonic acid is risedronic acid or a pharmaceutically acceptable salt thereof. 9. The method of claim 5 wherein said bisphosphonic acid is risedronic acid or a pharmaceutically acceptable salt thereof. 10. The method of claim 1 wherein said pharmaceutical composition is a solid pharmaceutical composition. 11. The method of claim 3 wherein said pharmaceutical composition is a solid pharmaceutical composition. 12. The method of claim 5 wherein said pharmaceutical composition is a solid pharmaceutical composition. 13. The method of claim 6 wherein said pharmaceutical composition is a solid pharmaceutical composition. 14. The method of claim 8 wherein said pharmaceutical composition is a solid pharmaceutical composition. 15. The method of claim 9 wherein said pharmaceutical composition is a solid pharmaceutical composition. 16. A method for treating or inhibiting osteoporosis consisting of orally administering to a subject in need of such treatment, once monthly, a pharmaceutical composition comprising from about 100 mg to about 150 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to about 100mg to about 150mg of said bisphosphonic acid. 17. The method according to claim 16, wherein the pharmaceutical composition comprises about 100 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to about 100 mg of bisphosphonic acid. 18. The method according to claim 16, wherein the pharmaceutical composition comprises about 150 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to about 150 mg of bisphosphonic acid. 19. The method of claim 16 wherein the pharmaceutical composition comprises 100 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to 100 mg of bisphosphonic acid. 20. The method of claim 16 wherein the pharmaceutical composition comprises 150 mg of bisphosphonic acid or an amount of a pharmaceutically acceptable salt thereof that is equivalent to 150 mg of bisphosphonic acid. 21. The method of claim 16 wherein said bisphosphonic acid is risedronic acid or a pharmaceutically acceptable salt thereof. 22. The method of claim 17 wherein said bisphosphonic acid is risedronic acid or a pharmaceutically acceptable salt thereof. 23. The method of claim 18 wherein said bisphosphonic acid is risedronic acid or a pharmaceutically acceptable salt thereof. 24. The method of claim 20 wherein said bisphosphonic acid is risedronic acid or a pharmaceutically acceptable salt thereof. 25. The method of claim 16 wherein said pharmaceutical composition is a solid pharmaceutical composition. 26. The method of claim 18 wherein said pharmaceutical composition is a solid pharmaceutical composition. 27. The method of claim 20 wherein said pharmaceutical composition is a solid pharmaceutical composition. 28. The method of claim 16 wherein said pharmaceutical composition is a solid pharmaceutical composition. 29. The method of claim 18 wherein said pharmaceutical composition is a solid pharmaceutical composition. 30. The method of claim 20 wherein said pharmaceutical composition is a solid pharmaceutical composition. once monthly on a single day, a pharmaceutical composition comprising from about 100 mg to about 150 mg of bisphosphonic acid acceptable salt thereof that is eguivalent to from about 100 mg to about 150 mg of bisphosphonic acid.